Updated guidance on the management of COVID-19 :: from an American Thoracic Society/European Respiratory Society coordinated International Task Force (29 July 2020)

Chunxue Bai; Sanjay H. Chotirmall; Jordi Rello; George A. Alba; Leo C. Ginns; Jerry A. Krishnan; Robert Rogers; Elisabeth Bendstrup; Pierre-Regis Burgel; James D. Chalmers; Abigail Chua; Kristina A. Crothers; Abhijit Duggal; Yeon Wook Kim; John Laffey; Carlos M. Luna; Michael S. Niederman; Ganesh Raghu; Julio A. Ramirez; Jordi Riera del Brio; Oriol Roca; Maximiliano Tamae-Kakazu; Antoni Torres; Richard R. Watkins; Miriam Barrecheguren; Mirko Belliato; Hassan A. Chami; Rongchang Chen; Gustavo A. Cortes-Puentes; Charles Delacruz; Margaret M. Hayes; Leo M. A. Heunks; Steven R. Holets; Catherine L. Hough; Sugeet Jagpal; Kyeongman Jeon; Takeshi Johkoh; May M. Lee; Janice Liebler; Gerry N. McElvaney; Ari Moskowitz; Richard A. Oeckler; Iñigo Ojanguren; Anthony O'Regan; Mathias W. Pletz; Chin Kook Rhee; Marcus J. Schultz; Enrico Storti; Charlie Strange; Carey C. Thomson; Francesca J. Torriani; Xun Wang; Wim A Wuyts; Tao Xu; Dawei Yang; Ziqiang Zhang; Kevin C. Wilson

doi:10.1183/16000617.0287-2020

Updated guidance on the management of COVID-19 : from an American Thoracic Society/European Respiratory Society coordinated International Task Force (29 July 2020)

Chunxue Bai, Sanjay H. Chotirmall, Jordi Rello, George A. Alba, Leo C. Ginns, Jerry A. Krishnan, Robert Rogers, Elisabeth Bendstrup, Pierre-Regis Burgel, James D. Chalmers, Abigail Chua, Kristina A. Crothers, Abhijit Duggal, Yeon Wook Kim, John Laffey, Carlos M. Luna, Michael S. Niederman, Ganesh Raghu, Julio A. Ramirez, Jordi Riera del BrioOriol Roca, Maximiliano Tamae-Kakazu, Antoni Torres, Richard R. Watkins, Miriam Barrecheguren, Mirko Belliato, Hassan A. Chami, Rongchang Chen, Gustavo A. Cortes-Puentes, Charles Delacruz, Margaret M. Hayes, Leo M. A. Heunks, Steven R. Holets, Catherine L. Hough, Sugeet Jagpal, Kyeongman Jeon, Takeshi Johkoh, May M. Lee, Janice Liebler, Gerry N. McElvaney, Ari Moskowitz, Richard A. Oeckler, Iñigo Ojanguren, Anthony O'Regan, Mathias W. Pletz, Chin Kook Rhee, Marcus J. Schultz, Enrico Storti, Charlie Strange, Carey C. Thomson, Francesca J. Torriani, Xun Wang, Wim A Wuyts, Tao Xu, Dawei Yang, Ziqiang Zhang, Kevin C. Wilson

Departament de Medicina

Producció científica: Contribució a revista › Article › Recerca › Avaluat per experts

92 Cites (Scopus)

Resum

Coronavirus disease 2019 (COVID-19) is a disease caused by severe acute respiratory syndrome-coronavirus-2. Consensus suggestions can standardise care, thereby improving outcomes and facilitating future research. An International Task Force was composed and agreement regarding courses of action was measured using the Convergence of Opinion on Recommendations and Evidence (CORE) process. 70% agreement was necessary to make a consensus suggestion. The Task Force made consensus suggestions to treat patients with acute COVID-19 pneumonia with remdesivir and dexamethasone but suggested against hydroxychloroquine except in the context of a clinical trial; these are revisions of prior suggestions resulting from the interim publication of several randomised trials. It also suggested that COVID-19 patients with a venous thromboembolic event be treated with therapeutic anticoagulant therapy for 3 months. The Task Force was unable to reach sufficient agreement to yield consensus suggestions for the post-hospital care of COVID-19 survivors. The Task Force fell one vote shy of suggesting routine screening for depression, anxiety and post-traumatic stress disorder. The Task Force addressed questions related to pharmacotherapy in patients with COVID-19 and the post-hospital care of survivors, yielding several consensus suggestions. Management options for which there is insufficient agreement to formulate a suggestion represent research priorities. For patients with acute COVID-19 pneumonia who require oxygen support, the International Task Force made suggestions for remdesivir and dexamethasone, but against hydroxychloroquine. Post-discharge management of COVID-19 survivors is a research priority.

Idioma original	Anglès
Revista	European Respiratory Review
Volum	29
DOIs	https://doi.org/10.1183/16000617.0287-2020
Estat de la publicació	Publicada - 2020

Accés al document

10.1183/16000617.0287-2020

https://ddd.uab.cat/record/238593Llicència: Creative Commons Reconeixement No Comercial

Altres arxius i enllaços

https://www.scopus.com/pages/publications/85092418767

Com citar-ho

Bai, C., Chotirmall, S. H., Rello, J., Alba, G. A., Ginns, L. C., Krishnan, J. A., Rogers, R., Bendstrup, E., Burgel, P.-R., Chalmers, J. D., Chua, A., Crothers, K. A., Duggal, A., Kim, Y. W., Laffey, J., Luna, C. M., Niederman, M. S., Raghu, G., Ramirez, J. A., ... Wilson, K. C. (2020). Updated guidance on the management of COVID-19 : from an American Thoracic Society/European Respiratory Society coordinated International Task Force (29 July 2020). European Respiratory Review, 29. https://doi.org/10.1183/16000617.0287-2020

@article{c00d113bacbd47b0a4791f372a1d4c99,

title = "Updated guidance on the management of COVID-19 :: from an American Thoracic Society/European Respiratory Society coordinated International Task Force (29 July 2020)",

abstract = "Coronavirus disease 2019 (COVID-19) is a disease caused by severe acute respiratory syndrome-coronavirus-2. Consensus suggestions can standardise care, thereby improving outcomes and facilitating future research. An International Task Force was composed and agreement regarding courses of action was measured using the Convergence of Opinion on Recommendations and Evidence (CORE) process. 70\% agreement was necessary to make a consensus suggestion. The Task Force made consensus suggestions to treat patients with acute COVID-19 pneumonia with remdesivir and dexamethasone but suggested against hydroxychloroquine except in the context of a clinical trial; these are revisions of prior suggestions resulting from the interim publication of several randomised trials. It also suggested that COVID-19 patients with a venous thromboembolic event be treated with therapeutic anticoagulant therapy for 3 months. The Task Force was unable to reach sufficient agreement to yield consensus suggestions for the post-hospital care of COVID-19 survivors. The Task Force fell one vote shy of suggesting routine screening for depression, anxiety and post-traumatic stress disorder. The Task Force addressed questions related to pharmacotherapy in patients with COVID-19 and the post-hospital care of survivors, yielding several consensus suggestions. Management options for which there is insufficient agreement to formulate a suggestion represent research priorities. For patients with acute COVID-19 pneumonia who require oxygen support, the International Task Force made suggestions for remdesivir and dexamethasone, but against hydroxychloroquine. Post-discharge management of COVID-19 survivors is a research priority.",

keywords = "CODIV-19",

author = "Chunxue Bai and Chotirmall, \{Sanjay H.\} and Jordi Rello and Alba, \{George A.\} and Ginns, \{Leo C.\} and Krishnan, \{Jerry A.\} and Robert Rogers and Elisabeth Bendstrup and Pierre-Regis Burgel and Chalmers, \{James D.\} and Abigail Chua and Crothers, \{Kristina A.\} and Abhijit Duggal and Kim, \{Yeon Wook\} and John Laffey and Luna, \{Carlos M.\} and Niederman, \{Michael S.\} and Ganesh Raghu and Ramirez, \{Julio A.\} and \{Riera del Brio\}, Jordi and Oriol Roca and Maximiliano Tamae-Kakazu and Antoni Torres and Watkins, \{Richard R.\} and Miriam Barrecheguren and Mirko Belliato and Chami, \{Hassan A.\} and Rongchang Chen and Cortes-Puentes, \{Gustavo A.\} and Charles Delacruz and Hayes, \{Margaret M.\} and Heunks, \{Leo M. A.\} and Holets, \{Steven R.\} and Hough, \{Catherine L.\} and Sugeet Jagpal and Kyeongman Jeon and Takeshi Johkoh and Lee, \{May M.\} and Janice Liebler and McElvaney, \{Gerry N.\} and Ari Moskowitz and Oeckler, \{Richard A.\} and I{\~n}igo Ojanguren and Anthony O'Regan and Pletz, \{Mathias W.\} and Rhee, \{Chin Kook\} and Schultz, \{Marcus J.\} and Enrico Storti and Charlie Strange and Thomson, \{Carey C.\} and Torriani, \{Francesca J.\} and Xun Wang and Wuyts, \{Wim A\} and Tao Xu and Dawei Yang and Ziqiang Zhang and Wilson, \{Kevin C.\}",

year = "2020",

doi = "10.1183/16000617.0287-2020",

language = "English",

volume = "29",

journal = "European Respiratory Review",

issn = "0905-9180",

publisher = "European Respiratory Society",

}

Bai, C, Chotirmall, SH, Rello, J, Alba, GA, Ginns, LC, Krishnan, JA, Rogers, R, Bendstrup, E, Burgel, P-R, Chalmers, JD, Chua, A, Crothers, KA, Duggal, A, Kim, YW, Laffey, J, Luna, CM, Niederman, MS, Raghu, G, Ramirez, JA, Riera del Brio, J, Roca, O, Tamae-Kakazu, M, Torres, A, Watkins, RR, Barrecheguren, M, Belliato, M, Chami, HA, Chen, R, Cortes-Puentes, GA, Delacruz, C, Hayes, MM, Heunks, LMA, Holets, SR, Hough, CL, Jagpal, S, Jeon, K, Johkoh, T, Lee, MM, Liebler, J, McElvaney, GN, Moskowitz, A, Oeckler, RA, Ojanguren, I, O'Regan, A, Pletz, MW, Rhee, CK, Schultz, MJ, Storti, E, Strange, C, Thomson, CC, Torriani, FJ, Wang, X, Wuyts, WA, Xu, T, Yang, D, Zhang, Z & Wilson, KC 2020, 'Updated guidance on the management of COVID-19 : from an American Thoracic Society/European Respiratory Society coordinated International Task Force (29 July 2020)', European Respiratory Review, vol. 29. https://doi.org/10.1183/16000617.0287-2020

TY - JOUR

T1 - Updated guidance on the management of COVID-19 :

T2 - from an American Thoracic Society/European Respiratory Society coordinated International Task Force (29 July 2020)

AU - Bai, Chunxue

AU - Chotirmall, Sanjay H.

AU - Rello, Jordi

AU - Alba, George A.

AU - Ginns, Leo C.

AU - Krishnan, Jerry A.

AU - Rogers, Robert

AU - Bendstrup, Elisabeth

AU - Burgel, Pierre-Regis

AU - Chalmers, James D.

AU - Chua, Abigail

AU - Crothers, Kristina A.

AU - Duggal, Abhijit

AU - Kim, Yeon Wook

AU - Laffey, John

AU - Luna, Carlos M.

AU - Niederman, Michael S.

AU - Raghu, Ganesh

AU - Ramirez, Julio A.

AU - Riera del Brio, Jordi

AU - Roca, Oriol

AU - Tamae-Kakazu, Maximiliano

AU - Torres, Antoni

AU - Watkins, Richard R.

AU - Barrecheguren, Miriam

AU - Belliato, Mirko

AU - Chami, Hassan A.

AU - Chen, Rongchang

AU - Cortes-Puentes, Gustavo A.

AU - Delacruz, Charles

AU - Hayes, Margaret M.

AU - Heunks, Leo M. A.

AU - Holets, Steven R.

AU - Hough, Catherine L.

AU - Jagpal, Sugeet

AU - Jeon, Kyeongman

AU - Johkoh, Takeshi

AU - Lee, May M.

AU - Liebler, Janice

AU - McElvaney, Gerry N.

AU - Moskowitz, Ari

AU - Oeckler, Richard A.

AU - Ojanguren, Iñigo

AU - O'Regan, Anthony

AU - Pletz, Mathias W.

AU - Rhee, Chin Kook

AU - Schultz, Marcus J.

AU - Storti, Enrico

AU - Strange, Charlie

AU - Thomson, Carey C.

AU - Torriani, Francesca J.

AU - Wang, Xun

AU - Wuyts, Wim A

AU - Xu, Tao

AU - Yang, Dawei

AU - Zhang, Ziqiang

AU - Wilson, Kevin C.

PY - 2020

Y1 - 2020

N2 - Coronavirus disease 2019 (COVID-19) is a disease caused by severe acute respiratory syndrome-coronavirus-2. Consensus suggestions can standardise care, thereby improving outcomes and facilitating future research. An International Task Force was composed and agreement regarding courses of action was measured using the Convergence of Opinion on Recommendations and Evidence (CORE) process. 70% agreement was necessary to make a consensus suggestion. The Task Force made consensus suggestions to treat patients with acute COVID-19 pneumonia with remdesivir and dexamethasone but suggested against hydroxychloroquine except in the context of a clinical trial; these are revisions of prior suggestions resulting from the interim publication of several randomised trials. It also suggested that COVID-19 patients with a venous thromboembolic event be treated with therapeutic anticoagulant therapy for 3 months. The Task Force was unable to reach sufficient agreement to yield consensus suggestions for the post-hospital care of COVID-19 survivors. The Task Force fell one vote shy of suggesting routine screening for depression, anxiety and post-traumatic stress disorder. The Task Force addressed questions related to pharmacotherapy in patients with COVID-19 and the post-hospital care of survivors, yielding several consensus suggestions. Management options for which there is insufficient agreement to formulate a suggestion represent research priorities. For patients with acute COVID-19 pneumonia who require oxygen support, the International Task Force made suggestions for remdesivir and dexamethasone, but against hydroxychloroquine. Post-discharge management of COVID-19 survivors is a research priority.

AB - Coronavirus disease 2019 (COVID-19) is a disease caused by severe acute respiratory syndrome-coronavirus-2. Consensus suggestions can standardise care, thereby improving outcomes and facilitating future research. An International Task Force was composed and agreement regarding courses of action was measured using the Convergence of Opinion on Recommendations and Evidence (CORE) process. 70% agreement was necessary to make a consensus suggestion. The Task Force made consensus suggestions to treat patients with acute COVID-19 pneumonia with remdesivir and dexamethasone but suggested against hydroxychloroquine except in the context of a clinical trial; these are revisions of prior suggestions resulting from the interim publication of several randomised trials. It also suggested that COVID-19 patients with a venous thromboembolic event be treated with therapeutic anticoagulant therapy for 3 months. The Task Force was unable to reach sufficient agreement to yield consensus suggestions for the post-hospital care of COVID-19 survivors. The Task Force fell one vote shy of suggesting routine screening for depression, anxiety and post-traumatic stress disorder. The Task Force addressed questions related to pharmacotherapy in patients with COVID-19 and the post-hospital care of survivors, yielding several consensus suggestions. Management options for which there is insufficient agreement to formulate a suggestion represent research priorities. For patients with acute COVID-19 pneumonia who require oxygen support, the International Task Force made suggestions for remdesivir and dexamethasone, but against hydroxychloroquine. Post-discharge management of COVID-19 survivors is a research priority.

KW - CODIV-19

UR - https://www.scopus.com/pages/publications/85092418767

U2 - 10.1183/16000617.0287-2020

DO - 10.1183/16000617.0287-2020

M3 - Article

C2 - 33020069

SN - 0905-9180

VL - 29

JO - European Respiratory Review

JF - European Respiratory Review

ER -

Updated guidance on the management of COVID-19 : from an American Thoracic Society/European Respiratory Society coordinated International Task Force (29 July 2020)

Resum

Accés al document

Altres arxius i enllaços

Fingerprint

Com citar-ho